Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

PROGENICS PHARMACEUTICALS INC

Form 8-K October 25, 2004

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 25, 2004

Progenics Pharmaceuticals, Inc.
-----(Exact name of registrant as specified in its charter)

Delaware 000-23143 13-3379479 ------ (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)

Registrant's telephone number, including area code (914) 789-2800

(Former name or former address, if changed since last report.)

Section 8 - Other Events

Item 8.01 Other Events

Announcement that the Board of Directors has elected current directors Kurt W. Briner and Paul F. Jacobson each to serve as non-executive Co-Chairman of the Board. They assume the chairmanship from Progenics' founder, Paul J. Maddon, M.D., Ph.D., who maintains his positions as Chief Executive Officer, Chief Science Officer, and a Company director.

Section 9 - Financial Statements and Exhibits

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

Item 9.01 Financial Statement and Exhibits

(c) the following exhibits are filed with this report

Exhibit Number Description

99.1 Press release dated October 25, 2004

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROGENICS PHARMACEUTICALS, INC.

By: /s/ ROBERT A. MCKINNEY

Robert A. McKinney
Vice President, Finance & Operations

Date: October 25, 2004